Rossella Elisei

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/4949400/publications.pdf

Version: 2025-02-01

295 PR articles	16,984 PR citations	14772 62 PR h-index	14248 126 g-index
338 documents	23967 doc citations	11668 71 h-index	18863 citing authors

#	Article	IF	Citations
1	Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance. Journal of Clinical Endocrinology and Metabolism, 2025, 110, 685-692.	4.1	9
2	Histologic parameters driving completion thyroidectomy for papillary thyroid carcinoma in a high-volume institution: A retrospective observational study. American Journal of Surgery, 2025, 239, 116016.	1.7	1
3	The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma. Thyroid, 2025, 35, 387-396.	4.4	3
4	Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes. Surgery, 2025, 181, 109258.	1.8	4
5	Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series. Cancers, 2025, 17, 950.	3.8	0
6	Reproductive Factors, Sex Hormone Levels, and Differentiated Thyroid Cancer Risk: A Mendelian Randomization Study. Thyroid, 2025, 35, 433-443.	4.4	3
7	Genetic origin of multifocal sporadic medullary thyroid cancer and C-cell hyperplasia. European Journal of Endocrinology, 2025, 192, 737-743.	4.0	1
8	A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma. Oncologist, 2024, 29, 84-88.	3.4	4
9	Insights into highly selective RET inhibitors in medullary thyroid cancer. Current Opinion in Endocrine and Metabolic Research, 2024, 35, 100521.	1.0	1
10	Erectile Dysfunction in Patients Treated with Selpercatinib for RET -Altered Thyroid Cancer. Thyroid, 2024, 34, 1177-1180.	4.4	3
11	Insights into Ultrasound Features and Risk Stratification Systems in Pediatric Patients with Thyroid Nodules. Journal of Imaging, 2024, 10, 189.	2.8	2
12	Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature. Endocrine, 2024, 87, 243-251.	2.5	2
13	Neoplasia follicolare della tiroide non invasiva con caratteristiche nucleari di tipo papillare (NIFTP): unâ€™entitÃ clinica di tutto rispetto. L Endocrinologo, 2024, 25, 443-447.	0.0	0
14	Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone. Current Oncology, 2024, 31, 5528-5536.	3.0	2
15	Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma. Thyroid Research, 2023, 16, .	1.6	3
16	Outcomes of the Tall-Cell Variant of Papillary Thyroid Carcinoma in Patients with Different Ages: A 17-Year Mono-Institutional Experience. Cancers, 2023, 15, 2152.	3.8	6
17	Clinical Evolution of Sporadic Medullary Thyroid Carcinoma With Biochemical Incomplete Response After Initial Treatment. Journal of Clinical Endocrinology and Metabolism, 2023, 108, e613-e622.	4.1	13
18	Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test. Journal of Endocrinological Investigation, 2023, 46, 1663-1671.	2.8	10

#	Article	IF	Citations
19	Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response. Frontiers in Endocrinology, 2023, 14, .	3.9	2
20	Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features. Journal of Endocrinological Investigation, 2023, 46, 2165-2173.	2.8	6
21	Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe. Frontiers in Oncology, 2023, 13, .	2.6	9
22	Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing. Endocrine, 2023, 81, 206-215.	2.5	10
23	Cytological and Ultrasound Features of Thyroid Nodules Correlate With Histotypes and Variants of Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2023, 108, e1186-e1192.	4.1	9
24	Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas. JAMA Oncology, 2023, 9, 1132.	14.4	17
25	NF1gene inactivation acts as a tumor driver inRET/RAS-negative medullary thyroid carcinomas. European Journal of Endocrinology, 2023, 188, 430-437.	4.0	11
26	Iperparatiroidismo nel contesto della MEN2A: dalla genetica alla gestione clinica. L Endocrinologo, 2023, 24, 232-238.	0.0	0
27	Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib. Journal of the Endocrine Society, 2023, 7, .	0.3	1
28	Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance. Journal of the Endocrine Society, 2023, 7, .	0.3	2
29	Ultrasound features and risk stratification system in NIFT-P and other follicular-patterned thyroid tumors. European Journal of Endocrinology, 2023, 189, 175-182.	4.0	16
30	Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer. New England Journal of Medicine, 2023, 389, 1851-1861.	34.6	144
31	BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review. Journal of Clinical Medicine, 2023, 12, 6970.	2.5	3
32	IgG4 serum levels in Gravesâ€™ orbitopathy. Journal of Endocrinological Investigation, 2023, 47, 1711-1717.	2.8	2
33	Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments. Journal of Endocrinological Investigation, 2023, 47, 1165-1173.	2.8	7
34	Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. Seminars in Cancer Biology, 2022, 79, 197-202.	13.7	33
35	Thyroidectomies in Italy: A Population-Based National Analysis from 2001 to 2018. Thyroid, 2022, 32, 263-272.	4.4	15
36	Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center. Cancers, 2022, 14, 420.	3.8	13

#	Article	IF	Citations
37	Response to Letter to the Editor From Green and Gosmanov: â€œTall Cell Percentage Alone in PTC Without Aggressive Features Should not Guide Patientsâ€™ Clinical Managementâ€• Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2653-e2654.	4.1	0
38	Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. Oncologist, 2022, 27, 565-572.	3.4	34
39	Impact of energy-based devices in pediatric thyroid surgery. Journal of Pediatric Surgery, 2022, 57, 740-745.	2.0	1
40	Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Frontiers in Endocrinology, 2022, 13, .	3.9	36
41	Nutrition in Advanced Thyroid Cancer Patients. Nutrients, 2022, 14, 1298.	4.5	14
42	Clinicalâ€“Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma. Frontiers in Endocrinology, 2022, 13, .	3.9	14
43	Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses. Frontiers in Oncology, 2022, 12, .	2.6	25
44	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60â€‰mg Per Day Compared with the Cabozantinib Capsule at 140â€‰mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid, 2022, 32, 515-524.	4.4	15
45	Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3420-e3427.	4.1	15
46	Predictive Biomarkers in Thyroid Cancer. Frontiers in Oncology, 2022, 12, .	2.6	13
47	Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2195-2202.	4.1	34
48	Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma. International Journal of Molecular Sciences, 2022, 23, 7470.	4.4	10
49	Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-NaÃ¯ve RET -Mutant Medullary Thyroid Cancer. Future Oncology, 2022, 18, 3143-3150.	2.3	29
50	Understanding the effect of obesity on papillary thyroid cancer: is there a need for tailored diagnostic and therapeutic management?. Expert Review of Endocrinology and Metabolism, 2022, 17, 475-484.	2.9	5
51	Re: â€œSymptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problemâ€• by Nervo et al.. Thyroid, 2021, 31, 330-331.	4.4	2
52	First report of benign track seeding after robot-assisted transaxillary thyroid surgery. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, 42, 102811.	1.5	9
53	Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. Thyroid, 2021, 31, 1050-1055.	4.4	17
54	Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System. Thyroid, 2021, 31, 1056-1066.	4.4	5

#	Article	IF	Citations
55	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. Thyroid, 2021, 31, 224-232.	4.4	34
56	Multiethnic genomeâ€wide association study of differentiated thyroid cancer in the EPITHYR consortium. International Journal of Cancer, 2021, 148, 2935-2946.	4.3	22
57	A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. International Journal of Molecular Sciences, 2021, 22, 1726.	4.4	79
58	Thyroid cancer and COVID-19: experience at one single thyroid disease referral center. Endocrine, 2021, 72, 332-339.	2.5	12
59	Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. Journal of Endocrinological Investigation, 2021, 44, 2139-2151.	2.8	20
60	Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. International Journal of Molecular Sciences, 2021, 22, 3117.	4.4	61
61	[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2355-2366.	4.1	19
62	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. Journal of the Endocrine Society, 2021, 5, .	0.3	4
63	Tall cell percentage alone in PTC without aggressive features should not guide patientsâ€™ clinical management. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4109-e4117.	4.1	21
64	Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs. Cancers, 2021, 13, 3200.	3.8	24
65	Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4072-e4083.	4.1	19
66	Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution. Cancers, 2021, 13, 3123.	3.8	18
67	Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates. Journal of Endocrinological Investigation, 2021, 44, 2557-2566.	2.8	16
68	Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. Critical Reviews in Oncology/Hematology, 2021, 163, 103366.	5.0	10
69	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	4.1	57
70	Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?. Journal of Clinical Medicine, 2021, 10, 4068.	2.5	15
71	Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma. Cancers, 2021, 13, 94.	3.8	22
72	Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma. Biomolecules, 2021, 11, 1542.	4.2	6

#	Article	IF	Citations
73	RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency. Genes, 2021, 12, 35.	2.5	3
74	Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia. Cancers, 2021, 13, 5554.	3.8	8
75	La gestione multidisciplinare delle metastasi ossee nel carcinoma tiroideo. L Endocrinologo, 2021, , .	0.0	0
76	Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer. Endocrine Practice, 2020, 26, 58-71.	3.3	19
77	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e172-e180.	4.1	137
78	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	4.9	49
79	Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1124-e1134.	4.1	34
80	QualitÃ della vita nei pazienti con microcarcinoma papillare della tiroide in funzione del trattamento: tiroidectomia totale con o senza terapia radiometabolica ablativa. L Endocrinologo, 2020, 21, 397-398.	0.0	0
81	Obesity as a risk factor for thyroid cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 358-363.	2.3	57
82	A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion. Case Reports in Endocrinology, 2020, 2020, .	0.5	7
83	Response to Letter to the Editor: â€œActive Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Centerâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2690-e2691.	4.1	0
84	Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2845-e2852.	4.1	12
85	Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up. Endocrine, 2020, 68, 607-616.	2.5	12
86	Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. Frontiers in Endocrinology, 2020, 11, .	3.9	13
87	Polymorphisms Within the RET Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma. Thyroid, 2020, 30, 1579-1588.	4.4	6
88	Proteinuria is a late-onset adverse event in patients treated with cabozantinib. Journal of Endocrinological Investigation, 2020, 44, 95-103.	2.8	20
89	Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma. Endocrine, 2020, 72, 140-146.	2.5	2
90	Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?. International Journal of Cancer, 2020, 147, 2838-2846.	4.3	21

#	Article	IF	Citations
91	Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases. Endocrine Practice, 2020, 26, 807-817.	3.3	17
92	MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients. Journal of the Endocrine Society, 2020, 4, .	0.3	0
93	MON-486 Polygenic Susceptibility to Papillary Thyroid Cancer in Italian Subjects. Journal of the Endocrine Society, 2020, 4, .	0.3	0
94	Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. European Journal of Cancer, 2019, 118, 35-40.	4.9	85
95	Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas. Endocrine, 2019, 65, 623-629.	2.5	4
96	Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. Cancers, 2019, 11, 1516.	3.8	42
97	Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. Genes, 2019, 10, 698.	2.5	79
98	Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. IScience, 2019, 20, 324-336.	3.6	195
99	Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer. Case Reports in Endocrinology, 2019, 2019, 1-4.	0.5	5
100	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2520-2526.	4.1	21
101	Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Annales D'Endocrinologie, 2019, 80, 187-190.	0.3	18
102	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. Frontiers in Oncology, 2019, 9, .	2.6	4
103	Management of Medullary Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 285-301.	3.5	91
104	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid, 2019, 29, 7-26.	4.4	154
105	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 213-220.	21.8	128
106	Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan. European Thyroid Journal, 2019, 8, 90-95.	0.9	13
107	mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases. Molecular and Cellular Endocrinology, 2019, 479, 93-102.	3.4	8
108	Features and outcome of differentiated thyroid carcinoma associated with Gravesâ€™ disease: results of a large, retrospective, multicenter study. Journal of Endocrinological Investigation, 2019, 43, 109-116.	2.8	25

#	Article	IF	Citations
109	A patient with MEN1 and endâ€'stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. Molecular and Clinical Oncology, 2018, , .	1.2	0
110	mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. Journal of Endocrinological Investigation, 2018, 41, 1389-1399.	2.8	19
111	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	4.6	69
112	Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. Head and Neck, 2018, 40, 1752-1758.	2.0	34
113	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. Frontiers in Endocrinology, 2018, 9, .	3.9	5
114	Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. Oncology Letters, 2018, , .	1.9	31
115	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without 131 I Ablation. Thyroid, 2018, 28, 871-879.	4.4	40
116	SP134PROTEINURIA IS A LATE ONSET ADVERSE EVENT IN PATIENTS TREATED WITH CABOZANTINIB: A SINGLE CENTER EXPERIENCE. Nephrology Dialysis Transplantation, 2018, 33, i388-i389.	0.8	1
117	The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans. Archives of Toxicology, 2018, 92, 2137-2140.	5.8	9
118	Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. Journal of Endocrinological Investigation, 2018, 41, 849-876.	2.8	199
119	Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. Thyroid, 2018, 28, 1318-1324.	4.4	7
120	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. European Journal of Cancer, 2017, 75, 213-221.	4.9	72
121	Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis. Expert Review of Endocrinology and Metabolism, 2017, 12, 207-214.	2.9	0
122	Response to Letter: â€œPostoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablationâ€• Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1785-1786.	4.1	2
123	Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 319-334.	5.1	29
124	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	4.1	97
125	Targeted Therapy in Thyroid Cancer: State of the Art. Clinical Oncology, 2017, 29, 316-324.	1.6	128
126	Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations. Journal of Surgical Oncology, 2017, 116, 1197-1199.	1.5	5

#	Article	IF	Citations
127	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Annals of Oncology, 2017, 28, 2813-2819.	10.0	213
128	Comunicare con la persona con cancro della tiroide in progressione. L Endocrinologo, 2017, 18, 224-230.	0.0	1
129	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nature Reviews Endocrinology, 2017, 13, 644-660.	32.0	424
130	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3091-3096.	4.1	2
131	Role of YAP-1 in Thyroid Tumor Progression and Outcome. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 581-585.	1.0	9
132	Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. Thyroid, 2017, 27, 1267-1276.	4.4	30
133	Use of low-dose radioiodine ablation for Gravesâ€™ orbitopathy: results of a pilot, perspective study in a small series of patients. Journal of Endocrinological Investigation, 2017, 41, 357-361.	2.8	5
134	Inherited variants in genes somatically mutated in thyroid cancer. PLoS ONE, 2017, 12, e0174995.	2.3	6
135	Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. OncoTargets and Therapy, 2016, Volume 9, 6467-6477.	2.7	44
136	New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. Journal of Medical Genetics, 2016, 53, 729-734.	3.8	81
137	Reply to the Letter to the Editor by Sollini M et al.. Journal of Endocrinological Investigation, 2016, 39, 487-488.	2.8	2
138	Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. DNA Repair, 2016, 41, 27-31.	2.5	8
139	Runs of homozygosity and inbreeding in thyroid cancer. BMC Cancer, 2016, 16, .	2.9	20
140	Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer, 2016, 122, 3856-3864.	4.0	90
141	Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4413-4420.	4.1	52
142	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. European Thyroid Journal, 2016, 5, 187-194.	0.9	13
143	Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. Archives of Toxicology, 2016, 90, 3099-3109.	5.8	9
144	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	4.1	195

#	Article	IF	Citations
145	A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nature Reviews Endocrinology, 2016, 12, 192-202.	32.0	325
146	A Comprehensive Meta-analysis of Caseâ€“Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 700-713.	1.1	26
147	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research, 2016, 22, 44-53.	6.8	220
148	Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. Journal of Endocrinological Investigation, 2016, 40, 55-62.	2.8	38
149	Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age. Current Pediatric Reviews, 2016, 12, 280-285.	1.7	9
150	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodineâ€refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer, 2015, 121, 2749-2756.	4.0	175
151	Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. Scientific Reports, 2015, 5, .	3.4	24
152	Cabozantinib: an orphan drug for thyroid cancer. Expert Opinion on Orphan Drugs, 2015, 3, 1469-1477.	1.0	2
153	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4387-4395.	4.1	12
154	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 2015, 372, 621-630.	34.6	1,845
155	Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1316-1324.	4.1	279
156	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	4.4	2,168
157	Effects of radioiodine treatment for differentiated thyroid cancer on testis function. Clinical Endocrinology, 2015, 82, 295-299.	2.3	20
158	Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?. Clinical Endocrinology, 2015, 82, 892-899.	2.3	47
159	Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. Journal of Endocrinological Investigation, 2015, 39, 341-347.	2.8	32
160	Thyroid carcinoma in thyrotoxic patients treated by surgery. Journal of Endocrinological Investigation, 2014, 11, 107-112.	2.8	36
161	Expression of calcitonin gene-related peptide in medullary thyroid cancer. Journal of Endocrinological Investigation, 2014, 15, 539-542.	2.8	11
162	Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. Journal of Endocrinological Investigation, 2014, 16, 329-332.	2.8	3

#	Article	IF	Citations
163	Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. Journal of Endocrinological Investigation, 2014, 16, 511-519.	2.8	17
164	Muscle autoantigens in thyroid associated ophthalmopathy: The limits of molecular genetics. Journal of Endocrinological Investigation, 2014, 16, 533-540.	2.8	2
165	Post-surgical follow-up of differentiated thyroid cancer. Journal of Endocrinological Investigation, 2014, 18, 165-166.	2.8	8
166	Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT). Journal of Endocrinological Investigation, 2014, 19, 230-235.	2.8	2
167	RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance. Journal of Endocrinological Investigation, 2014, 23, 328-338.	2.8	15
168	Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. Journal of Endocrinological Investigation, 2014, 24, 445-447.	2.8	3
169	Diagnosi genetica del carcinoma midollare della tiroide: implicazioni diagnostiche e terapeutiche. L Endocrinologo, 2014, 5, 39-46.	0.0	0
170	Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan. Journal of Endocrinological Investigation, 2014, 27, 866-869.	2.8	6
171	Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. Journal of Endocrinological Investigation, 2014, 27, 557-561.	2.8	10
172	Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. Journal of Endocrinological Investigation, 2014, 27, 636-642.	2.8	1
173	Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. Journal of Endocrinological Investigation, 2014, 29, 131-135.	2.8	23
174	Retinoic acid receptor Î²2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2â€²-deoxycytidine treatment. Journal of Endocrinological Investigation, 2014, 31, 724-730.	2.8	16
175	Correlazione genotipo-fenotipo nelle MEN 2: stato dellâ€™arte dopo 15 anni di conoscenze. L Endocrinologo, 2014, 11, 94-101.	0.0	0
176	Nuove indicazioni allâ€™impiego del TSH umano ricombinante (rhTSH) e basse attivitÃ di 131I nella radioablazione del residuo tiroideo post-chirurgico. L Endocrinologo, 2014, 14, 255-260.	0.0	0
177	Novel Genome-Wide Association Studyâ€“Based Candidate Loci for Differentiated Thyroid Cancer Risk. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2084-E2092.	4.1	44
178	Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Caseâ€“Control Studies. Thyroid, 2014, 24, 966-974.	4.4	108
179	FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment. Thyroid, 2014, 24, 339-346.	4.4	27
180	Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. Journal of Endocrinological Investigation, 2014, 37, 967-972.	2.8	9

#	Article	IF	Citations
181	Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. Thyroid, 2014, 24, 232-240.	4.4	140
182	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, The, 2014, 384, 319-328.	62.3	1,501
183	Molecular Profiles of Papillary Thyroid Tumors Have Been Changing in the Last Decades: How Could We Explain It?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 412-414.	4.1	11
184	Il carcinoma tiroideo: nuove prospettive terapeutiche. L Endocrinologo, 2014, 15, 28-35.	0.0	0
185	How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level. Endocrinology and Metabolism Clinics of North America, 2014, 43, 331-344.	3.5	16
186	Incidental versus clinically evident thyroid cancer: A 5â€year followâ€up study. Head and Neck, 2013, 35, 408-412.	2.0	7
187	Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. Thyroid Research, 2013, 6, S2.	1.6	30
188	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	16.6	859
189	Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutation Research - Reviews in Mutation Research, 2013, 752, 36-44.	4.1	81
190	Genome-Wide Association Study on Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1674-E1681.	4.1	122
191	Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement. Thyroid, 2013, 23, 1211-1225.	4.4	165
192	Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series. Thyroid, 2013, 23, 50-57.	4.4	166
193	Medullary Thyroid Cancer Secreting Carbohydrate Antigen 19-9 (Ca 19-9): A Fatal Case Report. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3550-3554.	4.1	26
194	TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. International Journal of Cancer, 2013, 133, 2843-2851.	4.3	30
195	Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2693-2700.	4.1	62
196	Cabozantinib (XL184) for the Treatment of Locally Advanced or Metastatic Progressive Medullary Thyroid Cancer. Future Oncology, 2013, 9, 1083-1092.	2.3	80
197	TheBRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4390-4398.	4.1	231
198	Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1758-E1765.	4.1	86

#	Article	IF	Citations
199	The Timing of Total Thyroidectomy in RET Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 426-435.	4.1	133
200	Advances in the follow-up of differentiated or medullary thyroid cancer. Nature Reviews Endocrinology, 2012, 8, 466-475.	32.0	81
201	Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. Molecular and Cellular Endocrinology, 2012, 348, 176-182.	3.4	22
202	Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer. Thyroid, 2012, 22, 476-481.	4.4	68
203	Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival inÂanaplastic thyroid cancer. Surgery, 2012, 152, 1078-1087.	1.8	47
204	Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2. Journal of Oncology, 2012, 2012, 1-15.	3.9	89
205	RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Frontiers in Endocrinology, 2012, 3, .	3.9	145
206	Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. Molecular and Cellular Endocrinology, 2012, 355, 41-48.	3.4	16
207	RET point mutations in Thyroid Carcinoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.2	0
208	RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clinical Endocrinology, 2011, 74, 241-247.	2.3	114
209	Evidences that the polymorphism Proâ€282â€Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. International Journal of Cancer, 2011, 129, 2816-2824.	4.3	29
210	Higher Intratumoral Expression of CD1a, Tryptase, and CD68 in a Follicular Variant of Papillary Thyroid Carcinoma Compared to Adenomas: Correlation with Clinical and Pathological Parameters. Thyroid, 2011, 21, 1209-1215.	4.4	40
211	Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4197-4205.	4.1	175
212	Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1516-1527.	4.1	210
213	Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. Journal of Pediatric Surgery, 2010, 45, 1610-1616.	2.0	19
214	Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4171-4179.	4.1	81
215	A Morpho-Molecular Diagnosis of Papillary Thyroid Carcinoma: BRAF V600E Detection as an Important Tool in Preoperative Evaluation of Fine-Needle Aspirates. Thyroid, 2009, 19, 837-842.	4.4	81
216	Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2â€²-deoxycytidine and retinoic acid. Molecular and Cellular Endocrinology, 2009, 307, 142-148.	3.4	42

#	Article	IF	Citations
217	Surgical Treatment of Low- and Intermediate-Risk Papillary Thyroid Cancer with Minimally Invasive Video-Assisted Thyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1618-1622.	4.1	96
218	T cell responses to orbital antigens in thyroid-associated ophthalmopathy. Clinical and Experimental Immunology, 2008, 96, 329-334.	3.4	4
219	Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 941-953.	5.1	83
220	Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Molecular and Cellular Endocrinology, 2008, 291, 57-62.	3.4	55
221	Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 682-687.	4.1	514
222	BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-Related Cancer, 2008, 15, 511-520.	3.5	145
223	Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2729-2736.	4.1	52
224	BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3943-3949.	4.1	502
225	Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clinical Endocrinology, 2007, .	2.3	151
226	RET Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4725-4729.	4.1	251
227	Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocrine-Related Cancer, 2007, 14, 1099-1105.	3.5	49
228	Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Human Pathology, 2007, 38, 1482-1488.	2.3	18
229	Lymphocyte and Immature Dendritic Cell Infiltrates in Differentiated, Poorly Differentiated, and Undifferentiated Thyroid Carcinoma. Thyroid, 2007, 17, 389-393.	4.4	82
230	Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma. Thyroid, 2007, 17, 381-388.	4.4	65
231	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2007, 54, 390.e1-390.e16.	1.0	0
232	The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3511-3516.	4.1	100
233	Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4085-4090.	4.1	384
234	Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 926-932.	4.1	420

#	Article	IF	Citations
235	Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2389-2395.	4.1	42
236	Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. Surgical Endoscopy and Other Interventional Techniques, 2006, 21, 120-123.	2.3	56
237	All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor Î² Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2403-2411.	4.1	43
238	Influence of Human Body Composition on Serum Peak Thyrotropin (TSH) after Recombinant Human TSH Administration in Patients with Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4047-4050.	4.1	26
239	RET/PTC3 Rearrangement and Thyroid Differentiation Gene Analysis in a Struma Ovarii Fortuitously Revealed by Elevated Serum Thyroglobulin Concentration. Thyroid, 2005, 15, 1355-1361.	4.4	25
240	Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 124-127.	4.1	219
241	A New Germline RET Mutation Apparently Devoid of Transforming Activity Serendipitously Discovered in a Patient with Atrophic Autoimmune Thyroiditis and Primary Ovarian Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4810-4816.	4.1	18
242	Medullary and Papillary Tumors Are Frequently Associated in the Same Thyroid Gland without Evidence of Reciprocal Influence in Their Biologic Behavior. Thyroid, 2004, 14, 946-952.	4.4	72
243	RET Exon 11 (G691S) Polymorphism Is Significantly More Frequent in Sporadic Medullary Thyroid Carcinoma Than in the General Population. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3579-3584.	4.1	113
244	Low Specificity of Blood Thyroglobulin Messenger Ribonucleic Acid Assay Prevents Its Use in the Follow-Up of Differentiated Thyroid Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 33-39.	4.1	56
245	Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 163-168.	4.1	495
246	Initial therapy of differentiated thyroid carcinoma: an update on surgery and radioiodine. Annales D'Endocrinologie, 2004, 65, 509-510.	0.3	0
247	BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2414-2420.	4.1	262
248	Identification of a Novel Point Mutation in the RET Gene (Ala883Thr), Which Is Associated with Medullary Thyroid Carcinoma Phenotype Only in Homozygous Condition. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5823-5827.	4.1	67
249	Authorsâ€™ Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodulesâ€”Will the Law Answer before Endocrinologists Do?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4770-4770.	4.1	0
250	Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. Clinical Endocrinology, 2003, 59, 500-506.	2.3	24
251	Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3668-3673.	4.1	395
252	Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens. Thyroid, 2003, 13, 765-770.	4.4	52

#	Article	IF	Citations
253	Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 748-754.	4.1	62
254	Simian Virus 40-Like Sequences from Early and Late Regions in Human Thyroid Tumors of Different Histotypes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 892-899.	4.1	30
255	Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4160-4165.	4.1	92
256	Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1499-1501.	4.1	267
257	Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4063-4068.	4.1	173
258	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. American Journal of Pathology, 2002, 160, 247-254.	3.4	105
259	Minimally invasive video-assisted thyroidectomy for papillary carcinoma: A prospective study of its completeness. Surgery, 2002, 132, 1070-1074.	1.8	204
260	Thyroid diseases around Chernobyl: from autoimmune diseases to malignant tumors. International Congress Series, 2002, 1234, 175-183.	0.2	2
261	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying theRET/PTC1 rearrangement. International Journal of Cancer, 2002, 97, 608-614.	4.3	42
262	Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1499-1501.	4.1	67
263	RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3211-3216.	4.1	237
264	Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4092-4097.	4.1	234
265	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5686-5690.	4.1	169
266	Contralateral Papillary Thyroid Cancer is Frequent at Completion Thyroidectomy with No Difference in Low- and High-Risk Patients. Thyroid, 2001, 11, 877-881.	4.4	143
267	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5686-5690.	4.1	62
268	RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3211-3216.	4.1	187
269	Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4092-4097.	4.1	77
270	New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma. Clinical Endocrinology, 2000, 53, 131-136.	2.3	17

#	Article	IF	Citations
271	N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression. Thyroid, 2000, 10, 19-23.	4.4	160
272	Conditional Apoptosis Induced by Oncogenic Ras in Thyroid Cells. Molecular Endocrinology, 2000, 14, 1725-1738.	2.5	53
273	Involvement of Protein Kinase CÎµ (PKCÎµ) in Thyroid Cell Death. Journal of Biological Chemistry, 1999, 274, 23414-23425.	2.2	71
274	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer, 1998, 83, 2185-2193.	4.0	64
275	Identification of Rapid Turnover Transcripts Overexpressed in Thyroid Tumors and Thyroid Cancer Cell Lines: Use of a Targeted Differential RNA Display Method to Select for mRNA Subsets. Nucleic Acids Research, 1997, 25, 3823-3831.	15.5	38
276	Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1619-1622.	4.1	142
277	Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery, 1995, 118, 1031-1035.	1.8	81
278	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype.. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 867-871.	4.1	56
279	Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. European Journal of Cancer, 1994, 30, 171-174.	4.9	37
280	Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 826-829.	4.1	228
281	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 867-871.	4.1	48
282	Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor.. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 499-503.	4.1	84
283	Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer.. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 1401-1404.	4.1	202
284	Medullary Thyroid Cancer: An Immunohistochemical and Humoral Study Using Six Separate Antigens. American Journal of Clinical Pathology, 1991, 95, 300-308.	0.7	87
285	Demonstration of the Existence of the Alternatively Spliced Form of Thyroid Peroxidase in Normal Thyroid*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 700-702.	4.1	26
286	Studies with Recombinant Autoepitopes of Thyroid Peroxidase: Evidence Suggesting an Epitope Shared Between the Thyroid and the Gastric Parietal Cell. Autoimmunity, 1990, 8, 65-70.	3.1	39
287	Somatostatin in medullary thyroid cancer.In vitro andin vivo studies. Cancer, 1989, 63, 1189-1195.	4.0	47
288	Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation. Journal of Clinical Endocrinology and Metabolism, 0, , jc.2016-2860.	4.1	39

#	Article	IF	Citations
289	Systemic treatment of advanced, metastatic, medullary thyroid carcinoma. , 0, , .		3
290	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid, 0, 31, 1226-1234.	4.4	41
291	Calcitonin receptor expression in medullary thyroid carcinoma. PeerJ, 0, 5, e3778.	0.0	7
292	Prevalence and genetics of â€œde novoâ€•MEN2 syndromes. Journal of Clinical Endocrinology and Metabolism, 0, 110, e3559-e3565.	4.1	1
293	Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma. Thyroid, 0, 35, 1013-1023.	4.4	1
294	Highly-selected sporadic, apparently unifocal cN0 MTC may benefit from unilateral surgery. A proof of concept in a high-volume institution. Surgery, 0, 189, 109699.	1.8	0
295	Liquid Biopsy-Based RET Mutation Profiling to Guide RET Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease. Thyroid, 0, 36, 188-194.	4.4	0